pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP
CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
Infusion of MSC
Phase 2 · small molecule · Discordant Immunological Response in HIV Infected Subjects
Infusion of MSC for Discordant Immunological Response in HIV Infected Subjects is a Phase 2 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Internal code CeTMAd-VIH-2014
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lxo Ireland Designated Activity Company
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Discordant Immunological Response in HIV Infected Subjects
- Status
- completed
- Trials
- 1